Pravindra Kumar

This study determines the crystal structures of a cysteine-dependent hydrolase from Rhodococcus opacus in complex with various plastics and shows its ability to degrade polyethylene, polypropylene, and polystyrene.

The paper reports the crystal structures of KFDV NS5 methyltransferase and evaluates HC and CAPE as inhibitors against the enzyme.

This paper identifies a novel bacteriophage endolysin LysPH with broad antibacterial activity and elucidates its structural basis for substrate recognition and catalytic activation.

This study reveals how β-lactoglobulin binds PFAS compounds through structural analysis and molecular dynamics, showing hydrophobic and electrostatic interactions that stabilize the binding.

This study identifies herbacetin as an inhibitor of dengue virus NS5 methyltransferase, revealing its binding mechanism and potential as a scaffold for antiviral drugs.

This study demonstrates EstS1 esterase's ability to degrade PET plastic and its intermediate BHET, supported by kinetic, structural, and morphological analyses.

This paper evaluates three antibiotics as inhibitors of the SARS-CoV-2 N-protein's C-terminal domain (N-CTD), showing their binding affinity and structural interactions that disrupt RNA packaging.

This study identifies efavirenz's anti-CHIKV activity and shows it inhibits viral replication by targeting minus-sense RNA synthesis, suggesting its repurposing for antiviral therapy.

This study identifies a new molecular interaction between G3BP1 and SARS-CoV-2 N protein and shows small molecules disrupt this interaction, reducing viral replication.

This paper develops an in silico affinity maturation pipeline to enhance nanobody binding to the SARS-CoV-2 Omicron RBD, achieving three-fold improved affinity through computational and experimental validation.

This study characterizes the structural and mechanistic properties of EstS1 esterase, revealing its role in degrading phthalate diesters through a bi-bi ping-pong mechanism and covalent substrate binding.

This study enhances the affinity of SARS-CoV-2 neutralizing nanobodies through structure-guided mutations in CDRs, resulting in improved neutralization activity against pseudovirus.

This study evaluates the antiviral and anti-inflammatory effects of triterpenoids against SARS-CoV-2 by targeting viral proteases and host immune pathways.

This study identifies antivirals targeting multiple sites of SARS-CoV-2 RdRp complex through in-silico screening, SPR validation, and cell-based assays, showing potent antiviral effects.

This study develops a bivalent chimeric virus-like particle vaccine displaying CHIKV and SARS-CoV-2 RBD antigens, showing potent immunogenicity in mice.

This study identifies DUB inhibitors that target SARS-CoV-2 PLpro, inhibiting its proteolytic activity and restoring immune responses in a mouse model.

This study identifies antivirals targeting the NTD of SARS-CoV-2 N protein using structure-based drug repurposing and shows their effectiveness in inhibiting viral replication.